TCM
REGN icon

TruNorth Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

TruNorth Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13
Closed -$7.31K – 323
2025
Q3 		$7.31K Buy
+13
New +$7.35K ﹤0.01% 355

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

TruNorth Capital Management's REGN Position: Q4 2025 in Review

TruNorth Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 13 shares — an estimated $7.31K sold.

TruNorth Capital Management first reported a position in REGN in Q3 2025 and held it in 1 quarter. The position peaked at $7.31K in Q3 2025. 1,387 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • TruNorth Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • TruNorth Capital Management sold 13 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $7.31K.
  • TruNorth Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • TruNorth Capital Management's Regeneron Pharmaceuticals position peaked at $7.31K in Q3 2025.
  • 1,387 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on TruNorth Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.